Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)
ID: PAR-24-107Type: BOTH
Overview

Topic

Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: STTRPhase: BOTHYear: 2024

Topic Link

https://www.sbir.gov/node/2504553

Additional Information

https://grants.nih.gov/grants/guide/pa-files/PAR-24-107.html
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for solutions to enable regional clinician-to-clinician genomic medicine eConsult services. The purpose of this funding opportunity is to develop products or technologies that will support the development and sustainment of eConsult services in the field of genomic medicine. Small businesses can submit Small Business Technology Transfer (STTR) Phase I and Fast-Track grant applications. The main objectives of the SBIR and STTR Phase I are to establish the technical merit and feasibility of the proposed research and development efforts. The Phase II continues the R&D efforts to advance the technology toward commercialization. The funding opportunity is open for applications until May 31, 2024. The specific objectives include addressing barriers to setting up eConsult services, conducting outreach and education about eConsult services, and providing eConsults. Solutions of interest include technologies that allow diverse Electronic Health Record systems to transmit and manage eConsult requests, artificial intelligence and machine learning solutions for triaging and creating responses, services or technologies for managing the administration of eConsult services, and educational products for providers. The funding opportunity is part of a larger initiative to establish the Genomic Medicine eConsult Research Network. Data sharing is expected, and applicants are encouraged to align their data sets using the FAIR Guiding Principles. A pre-application webinar will be held on February 6, 2024, to provide an overview of the funding opportunity and answer questions.

    Files
    No associated files provided.
    Similar Opportunities
    Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for addressing health inequities in clinical diagnostics. The purpose of this funding opportunity is to encourage small businesses to develop improved or alternative clinical diagnostics that incorporate diverse patient groups and eliminate health disparities. The research should focus on identifying and addressing issues within clinical diagnostics that perpetuate health inequity. The projects may involve existing clinical diagnostics or propose new ones. Applicants are encouraged to consider social determinants of health during the development process and include input from relevant populations that experience health disparities. The funding opportunity accepts different types of projects, including those that address pigment variation in imaging devices, utilize equitable parameters instead of non-biological parameters like race, improve analytics or bioinformatics, develop clinical decision support tools, validate new technology, or further develop existing technology. The funding is available through the Small Business Innovation Research (SBIR) program, with Phase I and Phase II funding options. The open date for applications is March 5, 2024, and the close date is January 6, 2027. For more information, including specific research objectives and areas of interest, interested parties can visit the solicitation agency URL provided.
    Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed) - https://grants.nih.gov/grants/guide/PA-files/PAR-24-158.html
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for addressing health inequities in clinical diagnostics through their Small Business Innovation Research (SBIR) program. The purpose of this funding opportunity is to encourage small businesses to develop improved or alternative clinical diagnostics that incorporate diverse patient groups and address health disparities. The goal is to lay the groundwork for more equitable clinical diagnostics that lead to improved health, healthcare delivery, and the elimination of health disparities. The research objectives include developing clinical diagnostics that are accessible to populations that experience health disparities, considering social determinants of health during the development process, and including input from relevant populations. The funding opportunity accepts various types of projects, such as novel technologies addressing known issues in existing diagnostics, projects addressing health disparities in analytics or bioinformatics, and pilot or small-scale projects validating new technology. The funding is divided into different phases, including Phase I to establish technical feasibility and Phase II for further development and commercialization. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Sexual & Gender Minority Research Office (SGMRO) are also participating in this funding opportunity, each with their specific research priorities. The National Human Genome Research Institute (NHGRI) encourages comprehensive genomics research with commercial potential. The solicitation is currently open, with multiple application due dates throughout the year. For more information, refer to the solicitation agency URL provided.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required). This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The funding opportunity is open until September 6, 2026. For more information and to apply, visit the solicitation agency URL: link.
    Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed) - https://grants.nih.gov/grants/guide/PA-files/PAR-24-158.html
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for addressing health inequities in clinical diagnostics through their Small Business Innovation Research (SBIR) program. The purpose of this funding opportunity is to encourage small businesses to develop improved or alternative clinical diagnostics that address health disparities created by clinical laboratory assays and point-of-care devices that fail to incorporate diverse patient groups. The goal is to develop clinical diagnostics that are accessible to populations that experience health disparities and to eliminate health inequities. The research objectives include developing clinical diagnostics that meet or exceed the quality of existing diagnostics, considering social determinants of health during the development process, and including input from relevant populations that experience health disparities. The funding opportunity accepts various types of projects, such as novel technologies addressing known issues in existing diagnostics, projects addressing health inequities in analytics or bioinformatics, and pilot or small-scale projects validating new technology. The funding is available for both Phase I and Phase II projects, with the option for a Fast Track application. The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Sexual & Gender Minority Research Office, and the National Human Genome Research Institute are also participating in this funding opportunity.
    Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for technologies that improve minority health and eliminate health disparities. The purpose of this funding opportunity is to support small businesses in developing technologies, services, and products that engage and empower individuals and communities, with a focus on African Americans, Hispanics, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and Pacific Islanders, disadvantaged socioeconomic groups, underserved rural populations, and sexual and gender minorities. The goal is to lay the groundwork for sustainable health-promoting activities and interventions that lead to improved health, healthcare delivery, and the elimination of health disparities. The research objectives include improving access to care, developing culturally attuned interventions, detecting and measuring unhealthy social and environmental exposures, engaging and empowering individuals and communities, and utilizing digital health technologies. The funding is available through the Small Business Innovation Research (SBIR) program, and the solicitation is open until December 10, 2026. For more information, visit the solicitation agency URL: link.
    Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for technologies that improve minority health and eliminate health disparities. The purpose of this funding opportunity is to support small businesses in developing technologies, services, and products that engage and empower individuals and communities, with a focus on African Americans, Hispanics, American Indians and Alaska Natives, Asian Americans, Native Hawaiians and Pacific Islanders, disadvantaged socioeconomic groups, underserved rural populations, and sexual and gender minorities. The goal is to lay the groundwork for sustainable health-promoting activities and interventions that lead to improved health, healthcare delivery, and the elimination of health disparities. The research objectives include improving access to care, developing culturally attuned interventions, detecting and measuring unhealthy social and environmental exposures, engaging and empowering individuals and communities, promoting precision medicine, utilizing digital health technologies, and strengthening infrastructure and workforce for delivering care. The funding is available through the Small Business Innovation Research (SBIR) program, and the solicitation is open until December 10, 2026. For more information, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of unlicensed products, or administration of licensed products for unapproved indications. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, study management and oversight, safety monitoring, and regulatory activities. The project duration is not specified, but the solicitation is open until January 14, 2027. The funding specifics can be found on the grants.nih.gov website.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that are used for intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field and advance the translation of EVs into clinical applications. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. The projects should focus on large-scale GMP grade production and manufacturing challenges associated with the use of EVs as therapeutics. The application due dates are June 6th of each year from 2023 to 2025. For more information and to apply, visit the solicitation agency URL: link.
    Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)
    Active
    Department of Health and Human Services
    The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the industrialization and translation of extracellular vesicles (EVs) for use in regenerative medicine. EVs are membrane-enclosed carriers of bioactive substances that play a role in intercellular communication. This funding opportunity aims to support the development of novel EV-based therapeutic platforms for tissue and organ repair in regenerative medicine. The focus is on the production, manufacturing, and use of native or engineered EVs as therapeutics. The goal is to address challenges in the field, such as large-scale production and manufacturing of EVs for therapeutic use. The funding opportunity is open to small business concerns and offers both Phase I and Phase II grants. Phase I applications should focus on feasibility and therapeutic applications, while Phase II applications should optimize and scale-up technology platforms. The validation of therapeutic benefits is required for Phase II applications. The development of IND enabling therapeutic platforms that can work towards regulatory approval and commercialization is prioritized. Applications must include project milestones and should align with the goals of the funding opportunity. The application due dates are June 6th of each year from 2023 to 2025. For more information, visit the solicitation agency URL: link.